Get started

PHARMA

Small Pharma Big Backers and Partners - LONG SNG (Synairgen)Prudent Drug Discovery Company Low market cap ( appox £13m at time of writing ). Issues shares very rarely ( last placing nearly four years ago ). Has material interest in its work from larger partners ( Pharmaxis ). Sold interest in LOXL2 programme for £5m to Pharmaxis in December. Pharmaxis continues to fund and develop LOXL2 inhibitors and Synairgen retains interest across all fibrotic indications at circa 17% of all partnering proceeds. Potential of drug appears across multiple uses now ( not just lung-related ) and indications from Pharmaxis looking very good. Recent interviews from Pharmaxis management suggest a good chance of a deal with major pharma in H2. Low free float in the stock ( 60% in hands of major shareholders ). Major funds holding ( Woodford Investment Management and Lansdowne Partners ). High profile investors holding stakes ( Richard Griffiths and Leonard Licht ). These high profile investors have been raising, rather than reducing their stakes in the company, periodically. For a risky smallcap biotech stock it appears well placed to survive and thrive, regardless of the short term success of a sale/licencing deal of LOXL2 by Pharmaxis, making it considerably less risky than most biotech stocks in the long term. However, the indications and noises being made about LOXL2 by Pharmaxis are looking as positive as you could hope for, and backed up by them putting their money where their mouth is in the first place and increasing their stake for cash.
LSE:SNGLong
by richthenewbie
3
ASX Star Combo Pharma Star Combo Pharma has just started trading last week. It has a good run up to above $2. I believe this is Wave 1 of Elliot. The price has dropped a bit at writing and if I am not wrong, corrective wave 2 will probably hit between 0.5 to 0.618 in the next few days. If i were to trade, i would look for entry below $1.30 between 0.5 to 0.618 fibonacci. At writing, there was a bounce at 0.384 fib @ about $1.40. If my charts are correct, we are looking at corrective wave B of 2 then C down to 0.618 fib. We shall see. ABOUT THE COMPANY --- extracted from: www.afr.com A company that acquired the Living Healthy vitamins and health supplements brand from pharmacy chain Terry White Chemmart last year wants to make a big shift from being a contract manufacturer to launching its own brand. Star Combo Pharma has raised $7 million in an initial public offering at an issue price of 50¢, and will list on the ASX on Wednesday, with chairman Richard Allely outlining ambitious growth plans. The company signed a three-year distribution deal with Terry White Chemmart as part of the acquisition where the Living Healthy vitamins brand will be on the shelves of 450 of the group's pharmacies. Mr Allely said Star Combo currently generated about 70 per cent of its revenues through contract manufacturing for other vitamins companies in western Sydney. About 30 per cent of its revenues come from its own brands, which include Costar, Amax and J&K. Those three brands are largely sold in gift stores and duty free stores. The Living Healthy brand had undergone a rebadging and repackaging, and Star Combo was aiming to accelerate its growth. Between 20 and 30 individual product lines, known as stock-keeping units, would be on the shelves of Terry White Chemmart outlets around Australia. Star Combo was also eyeing a big push into China, to try to emulate in a smaller way the success of big players such as Blackmores and Swisse. At the issue price of 50¢, Star Combo has an indicative market capitalisation of $38 million. Mr Allely said the IPO had been oversubscribed and the company had been forced to scale back applications. The company made a net profit of $1.48 million in 2016-17 from revenues of $9.84 million. Net profit in 2015-16 was $1.59 million from revenues of $9.4 million.
ASX:S66Long
by paper_value
CELG Q1 2018 Earnings on 5/4 - Are Traders Rotating In or Out?What a tumultuous market. Celgene reports earnings on 5/4. Earnings play aside, are traders and investors rotating into or out of pharmaceuticals? The market doesn't know what to do with itself right now. With a Fed meeting taking place over the next couple days, Caterpillar's CFO claiming we've seen a "high water mark" with Q1 earnings, rate concerns, trade concerns, and historic geopolitical uncertainty (especially regarding Iran's nuclear program), some traders claim we've already seen April and May's strongly anticipated earnings rally. If that's true, 1. what a squishy rally, and 2. where do we go from here? Thanks in advance for lending me your attention! Pharmaceuticals are a wild card among the classical winners (usually, financials, materials, and energy) and losers (REITs, utilities, etc.) in a late-cycle rotation. It can be argued a lot of Wall Street cash has sought the arguably greener pastures of cryptocurrencies. But could we see prices move upward along the right side of the chart in pharmaceutical companies? CELG reports earnings on 5/4. Celgene took a dive on 4/30 on troubling news about a drug in its development pipeline. Did that drop make Celgene a bargain buy? CELG's drop on bad news has put it at technical support. The uncertainty of its earnings report and the market overall has it arguably priced cheap. Is Celgene a cheap buy in this market with a possible earnings surprise on 5/4 and upside potential with a rotation into pharma? Please like, follow, and share, and maybe we can have fun and do great things together. Thanks again! See it on the site: holsturr.com/category/markets/charts/ ** For speculative and research purposes only - good luck! **
CLong
by holsturr
SNSS short based on BB and RSIMY OPINION: Jumped into SNSS at this low signal of 4.24. This drop in share price occurred after recent earnings report on March 8th. This is a psychological pitfall, expecting shares to jump back between the middle and bottom Bands by mid week. THE FACTS: The company reported $0.21 earnings per share for the quarter Sunesis Pharmaceuticals has a 52 week low of $1.82 and a 52 week high of $7.69. Among 5 analysts covering Sunesis Pharmaceuticals, 2 have Buy rating, 1 Sell and 2 Hold.
SShort
by SoWaVvY
CPHI Win or Fail? (Fib with RSI and Ghost bars)Lets see what next week will bring! After a recent check, the 14-day RSIfor China Pharma Holdings (CPHI) is currently at 65.41, the 7-day stands at 78.81, and the 3-day is sitting at 94.30.Many professionals agree that realizing a loss is just as important as picking a winner, so I've also included a potential loss area to point out my opinion of when to abort mission. Price Target is anywhere form 0.60 to 0.72 by mid week. The stock has returned 21.95% weekly, which was maintained at 9.59% in the 1-month period. I'm looking forward to the upside of that return!
AMEX:CPHIShort
by SoWaVvY
Veeva Systems: One of my favourite stocks right nowI love it when fundamentals and technicals line up together. I am in general very bullish towards cloud-software companies, thats the future, especially when they have a footing in the pharma industry like veeva. This is a huge market and growing strongly year by year. The chart is a textbook bull flag. I am expecting a move into 80$ over the coming months. Longterm over the coming years we can also see prices above 100$. The only reasonable place to put a stop right now is below 50$. So do your own diligence and research, this is just my opinion towards this stock. Fundamental analysis by Morgan Stanley: Veeva Systems Inc VEEV, a cloud-computing company focused on the pharma and life sciences industry, is an underpriced asset within the broader SaaS universe, according to Morgan Stanley. The Analyst Morgan Stanley analyst Stan Zlotsky upgraded Veeva Systems from Equal-weight to Overweight and increased the price target from $69 to $72. The Thesis Veeva Systems has durable growth — fueled by an expanding $17-billion total addressable market — and margin potential that is not being reflected in current trading levels, Zlotsky said in a Tuesday note. A conservative setup into 2019 offers scope for estimates and shares to move up, he said. The company's best-in-class economics are likely to drive longer-term operating margin to 43 percent, representing the highest margin potential in Morgan Stanley's coverage universe, Zlotsky said. "Veeva's above average sales efficiency and a disciplined go-to-market has enabled the company to simultaneously deliver strong revenue growth and greater than 30-percent operating margins today, well above the 18-percent average among more mature SaaS peers," the analyst said. Morgan Stanley estimates 16-percent revenue growth on a CAGR basis to $1.7 billion and a 36-percent operating margin by calendar year 2023, resulting in free cash flow of $593 million. With the 12-percent pullback in Veeva Systems shares since June 2017 compared to a 14-percent gain for the SaaS peer group, Morgan Stanley sees an attractive entry point to rebuild positions in the shares.
NYSE:VEEVLong
by IamJeanPaul
2
NeuroMetrix, Inc, Low Float, Lands Deal With GlaxoSmithKlineNew and innovative product. Quell's proven technology is 5x more powerful on average than other over-the-counter pain relief devices. It is discreet and completely wearable to enable pain relief when your patients need it. Increased quarterly earnings growth. Low floater Resistance at at 3.00 range due to the preferred shares being exercisible at 2.83 Target is 2.50. Nice day trade potential. They just had the biggest trading volume in a very long time, by a long shot.
NASDAQ:NURO
by alipipefitter
1
INSY Target $23 FDA Cannabidiol Fast trackFDA Grants INSYS Therapeutics ‘Fast Track’ Designation for Cannabidiol (CBD) Oral Solution as INSYS Therapeutics, Inc. (NASDAQ:INSY), announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s cannabidiol (CBD) oral solution for the treatment of Prader-Willi syndrome, a rare and complex genetic disorder characterized by insatiable appetite in children that often leads to obesity and type 2 diabetes. “FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, a debilitating condition which currently does not have any approved products available,” said Steve Sherman, senior vice president of regulatory affairs for INSYS Therapeutics. “We plan to start the clinical development program for this promising therapy in late first quarter of 2018.” The most common known genetic cause of life-threatening obesity in children, Prader-Willi syndrome has a prevalence of approximately 1 in 15,000, according to the Prader-Willi Syndrome Association, occurring in males and females equally and in all races. “We are very encouraged by the FDA’s decision to put CBD for Prader-Willi on the Fast Track and believe it is good news for these young patients, their families and clinicians,” said Saeed Motahari, president and chief executive officer of INSYS Therapeutics. “This special regulatory designation represents a significant milestone in the company’s R&D program, which is focused on developing and delivering safe, effective and novel treatment options using cannabinoids and novel drug delivery technology for unmet medical needs.” About INSYS INSYS Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve patients’ quality of life. Using proprietary spray technology and capabilities to develop pharmaceutical cannabinoids, INSYS is developing a pipeline of products intended to address unmet medical needs and the clinical shortcomings of existing commercial products. Forward-Looking Statements This news release contains forward-looking statements including regarding (i) our belief that FDA’s Fast Track designation will enable an expedited regulatory review process for our proprietary formulation of CBD in the treatment of pediatric patients with Prader-Willi syndrome, (ii) our belief that Prader-Willi syndrome currently does not have any approved products available and that our proprietary CBD formulation has potential to be a viable treatment option and (iii) our plan to start the clinical development program for this promising therapy in late first quarter of 2018. These forward-looking statements are based on management’s expectations and assumptions as of the date of this news release; actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. These factors include, but are not limited to, risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2016 and subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this news release, and we undertake no obligation to publicly update or revise these statements, except as may be required by law.
ILong
by StockPicksNYC98
Teva strong resistence at 19.33, yet not a buyDespite the recent company's efforts to reduce its debit, from a technical point of view, I would be neutral with Teva until we will see a cross-over between slow 200d and fast 50d moving average on a daily chart pattern. For those who are aggressives MACD is still positive but keep in mind the resistence at 19.33 first and 20 after. Exhaustion gap betweeen 16 and 18 has been filled. Personally I see such movement as a prize for what the new CEO has done to reduce the impact of debit in short and mid term. Still 2018 will be critical to conferm that what has been undertaken is going toward in the right direction.
NYSE:TEVA
by TRADOMICS_
VRX imminent attack to 18 dollarsVRX after the correction largly expected, yesterday as demostrated a strong bullish counterattack closing the session slightly less than the short entry recovering mostly 100%. The pattern therefore shows clearly the uptrend line in place. Investors are considering a Q4 better than Q3 looking for new confirmation about debit reduction, so I expect price will move up, breaking down the barrier set at 18 dollars. In case of confirmation this would be a strong signal as Valeant is gaining back attention and potential turn around. Still there is a long way to go through, but what is important right now to highlight is that the trend has been confirmed.
VLong
by TRADOMICS_